Need for standardization of 18F-FDG PET/CT for treatment response assessments
about
State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PETRole of positron emission tomography for the monitoring of response to therapy in breast cancerImaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative ApproachPET/CT in Oncology: Current Status and Perspectives.Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional studyPerformance evaluation of the Ingenuity TF PET/CT scanner with a focus on high count-rate conditions.A Review of NIST Primary Activity Standards for (18)F: 1982 to 2013.Predicting outcomes in radiation oncology--multifactorial decision support systemsHarmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.Promise and pitfalls of quantitative imaging in oncology clinical trials.Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical PETPET/CT in Radiotherapy Planning for Head and Neck CancerAssociation Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma.Calibration test of PET scanners in a multi-centre clinical trial on breast cancer therapy monitoring using 18F-FLT.Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.Tumor quantification in clinical positron emission tomography.Comparison between kinetic modelling and graphical analysis for the quantification of [18F]fluoromethylcholine uptake in mice.18 F-FDG PET standard uptake values of the normal pons in children: establishing a reference value for diffuse intrinsic pontine glioma.New techniques for assessing response after hypofractionated radiotherapy for lung cancerMonitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer.Clinical oncologic applications of PET/MRI: a new horizon.Staging the axilla in breast cancer patients with ¹⁸F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?Validation of phantom-based harmonization for patient harmonization.Pulmonary imaging after stereotactic radiotherapy-does RECIST still apply?A novel approach to assess the treatment response using Gaussian random field in PET.Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.Whole-body direct 4D parametric PET imaging employing nested generalized Patlak expectation-maximization reconstruction.Optimization of brain PET imaging for a multicentre trial: the French CATI experience.Improved image quality in pinhole SPECT by accurate modeling of the point spread function in low magnification systems.Serial imaging using [18F]Fluorodeoxyglucose positron emission tomography and histopathologic assessment in predicting survival in a population of surgically resectable distal oesophageal and gastric adenocarcinoma following neoadjuvant therapy.(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.Summary report of the First International Workshop on PET/MR imaging, March 19-23, 2012, Tübingen, Germany.Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond.The engagement of FDG PET/CT image quality and harmonized quantification: from competitive to complementary.18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.Classification of early stage non-small cell lung cancers on computed tomographic images into histological types using radiomic features: interobserver delineation variability analysis.Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
P2860
Q27694674-45091F7E-AAC7-4B24-A754-87ADC9A85B15Q28080621-294D4822-3029-4C16-8453-964A077E31A3Q30491728-1CD0C895-7F1B-4C6B-AC75-1F03BC636465Q33665109-169DA99D-402F-44A6-8EB3-9BAB66C3682EQ35539538-5E394808-92A2-4EEA-A3B5-0929630E9B64Q35687966-657C021A-3C69-495E-A869-3FAECDEA0A08Q35804394-419B27B1-FEB7-4C5F-888B-186F10BCF52FQ36014711-67390FE4-91AB-4E9E-8AC2-F95228DA7F7EQ36214863-C40A7FC6-303D-416D-A597-C9BB55B24977Q36303765-967C22BC-3B3F-4851-AF66-2132643E5F7AQ36429831-E7D879C0-B527-4503-9570-7DB32CFFBCA1Q36454757-648F1393-9441-4B86-A8E4-C5D875ED3120Q36455944-799AE318-6F58-49BC-98CA-F3048492C09DQ36604985-C11DD3C5-9A53-4594-895D-6181BB2C6A7FQ36680859-E7D5220F-61F6-4E42-A86F-0D6300ED57C6Q36920672-95EDF706-DD95-413E-9BC2-46F9AB304F92Q37240835-0949AAFD-605C-407B-B481-03B3F307E563Q37342658-7335AF6A-1D1D-4985-A9AC-FC8A37271B8BQ37359926-23E30D0F-10B8-41EB-A57A-525EC17CF9D7Q37542423-252A6C5B-2171-4293-AB29-E2A878CC5AFDQ37670432-3A5317A5-CCD2-46B0-AB20-952B2B093A33Q37681293-E4704EFB-F022-4315-877E-64D67E00A9D5Q37711076-83C4F788-D92F-4436-97DB-3D2DAD242088Q37735166-11A4C1E3-331A-4AFE-9598-D4315A6986E7Q38020791-49C63FD0-3444-4214-ADC6-72D6694EB05DQ38808641-24D3685E-3D91-4EB4-A71F-B5221B1C9445Q38849150-9DE0BD04-34D8-45F9-96E3-CB373DB0E3A0Q38912360-0AEAF876-CE63-4EBF-97C9-6AC0B873C441Q39311162-79004E7F-BCE1-4997-9044-321A6AA4CB38Q39627244-2BE21808-DF82-4E7E-8787-1458AE76AB79Q39859165-26ADD29E-C121-4FF6-AB7E-6C9E4064BFABQ41478028-BDE54960-070E-4242-B838-C494ACD53DB0Q42094686-C3CC7382-D4FE-41B9-B550-A74588FB8A27Q42545669-B5C6B9E7-E7EF-4C6E-88AE-D49F080A6914Q43096930-583F4158-4246-495F-84E9-147282A399B7Q43234029-81C2CB9E-C832-418A-A4FF-C358F3DFFC65Q44453305-D8B75114-9C3D-41A2-9A7A-2BD9DC9D361BQ44750052-E42A278E-B6B0-49A4-A199-9DDA815B467BQ45943241-4F7C72B2-DF5D-4D86-886C-F4DB2CFAEAD0Q46150817-36C80C23-79E7-4777-ACF4-5147363D2B1B
P2860
Need for standardization of 18F-FDG PET/CT for treatment response assessments
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@ast
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@en
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@nl
type
label
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@ast
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@en
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@nl
prefLabel
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@ast
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@en
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@nl
P3181
P1476
Need for standardization of 18F-FDG PET/CT for treatment response assessments
@en
P304
P3181
P356
10.2967/JNUMED.110.085662
P407
P478
52 Suppl 2
P577
2011-12-01T00:00:00Z